hp568

HP568 is an orally bioavailable small molecule proteolysis-targeting chimera (PROTAC) developed by Hinova Pharmaceuticals. It functions as a potent estrogen receptor (ER) degrader, targeting both wild-type ER and clinically relevant ERα mutants. By catalyzing rapid proteasome-dependent degradation of the estrogen receptor, HP568 antagonizes ER signaling pathways implicated in the growth of hormone receptor-positive breast cancers. Preclinical studies have demonstrated significant antitumor activity and a favorable safety profile in animal models. The drug is currently being evaluated in Phase I/II clinical trials for patients with advanced or metastatic ER-positive/HER2-negative breast cancer[2][3][4][5].